Announced Sat, 23 May · 21:42 IST

Re-appointment of M/s. Lavanya & Associates as the Cost Auditors for FY 2026-27.

Management Changes View source PDF

RAINBOW · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹1358.00
prior close
₹1365.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-0.6-1.1-1.6-0.1+1.4+1.8-0.4-1.7-0.2+4.4+5.4+9.2
Up moveDown movePending
AI summary

Rainbow Children's Medicare held its Board meeting on May 23, 2026 and approved multiple items. The company reported audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026 with an unmodified opinion from statutory auditors S.R. Batliboi & Associates LLP. The Board recommended a final dividend of Rs 3.5 per share (35% on face value) for FY 2025-26, subject to shareholder approval at the 28th AGM scheduled for July 29, 2026. Key director re-appointments include Dr. Ramesh Kancharla as Chairman and Managing Director, Dr. Dinesh Kumar Chirla as Whole Time Director, and renewal of independent director terms for Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati. The cost auditor M/s. Lavanya & Associates LLP was re-appointed for FY 2026-27.

Likely market impact

This is a routine governance filing with no negative signals. The company delivered clean financials and continuity in leadership with shareholder-friendly dividend recommendation. The simultaneous re-appointments of multiple directors and auditors indicate stable governance.